title: Design of novel iron compounds as potential therapeutic agents against tuberculosis.
abstract: In the search for new therapeutic tools against tuberculosis two novel iron complexes, [Fe(L-H)(3)], with 3-aminoquinoxaline-2-carbonitrile N(1),N(4)-dioxide derivatives (L) as ligands, were synthesized, characterized by a combination of techniques, and in vitro evaluated. Results were compared with those previously reported for two analogous iron complexes of other ligands of the same family of quinoxaline derivatives. In addition, the complexes were studied by cyclic voltammetry and EPR spectroscopy. Cyclic voltammograms of the iron compounds showed several cathodic processes which were attributed to the reduction of the metal center (Fe(III)/Fe(II)) and the coordinated ligand. EPR signals were characteristic of magnetically isolated high-spin Fe(III) in a rhombic environment and arise from transitions between m(S) = ± 1/2 (g(eff) ~ 9) or m(S) = ± 3/2 (g(eff) ~ 4.3) states. Mössbauer experiments showed hyperfine parameters that are typical of high-spin Fe(III) ions in a not too distorted environment. The novel complexes showed in vitro growth inhibitory activity on Mycobacterium tuberculosis H(37)Rv (ATCC 27294), together with very low unspecific cytotoxicity on eukaryotic cells (cultured murine cell line J774). Both complexes showed higher inhibitory effects on M. tuberculosis than the "second-line" therapeutic drugs.
authors.affiliation: Facultad de Química, Cátedra de Química Inorgánica, Universidad de la República, Gral Flores 2124, C C 1157, 11800 Montevideo, Uruguay.
authors.forename: M Belén
authors.initials: MB
authors.lastname: Tarallo
authors.forename: Carolina
authors.initials: C
authors.lastname: Urquiola
authors.forename: Antonio
authors.initials: A
authors.lastname: Monge
authors.forename: Beatriz Parajón
authors.initials: BP
authors.lastname: Costa
authors.forename: Ronny R
authors.initials: RR
authors.lastname: Ribeiro
authors.forename: Antonio J
authors.initials: AJ
authors.lastname: Costa-Filho
authors.forename: Roberto C
authors.initials: RC
authors.lastname: Mercader
authors.forename: Fernando R
authors.initials: FR
authors.lastname: Pavan
authors.forename: Clarice Q F
authors.initials: CQ
authors.lastname: Leite
authors.forename: María H
authors.initials: MH
authors.lastname: Torre
authors.forename: Dinorah
authors.initials: D
authors.lastname: Gambino
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004563:Electrochemistry; D004578:Electron Spin Resonance Spectroscopy; D005296:Ferrous Compounds / Q000737:chemistry; D020128:Inhibitory Concentration 50; D058085:Iron Compounds / Q000737:chemistry*; D008024:Ligands; D008670:Metals / Q000737:chemistry; D051379:Mice; D008826:Microbial Sensitivity Tests; D008958:Models, Molecular; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011810:Quinoxalines / Q000737:chemistry; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D005296:Ferrous Compounds; D058085:Iron Compounds; D008024:Ligands; D008670:Metals; D011810:Quinoxalines